BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CDX-622 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CDX-622\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07330778-4598@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:CDX-622: Phase 1 readout est. (NCT07330778)
DESCRIPTION:CDX-622\, phase 1\, Asthma.\nStudy: A Study of CDX-622 in Parti
 cipants With Mild to Moderate Asthma\nEstimated primary completion: March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/cdx-622#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07330778
URL:https://assetmemo.bio/drug/cdx-622#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
